We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$197M
Cap. Flow
+$227M
Cap. Flow %
16.33%
Top 10 Hldgs %
54.77%
Holding
74
New
16
Increased
17
Reduced
14
Closed
17

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$61.8M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$41.4M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$39.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$38.1M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$30.1M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$31.2M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$26.9M
3
VERV
Verve Therapeutics
VERV
+$18.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15.8M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$280M
$233M 16.81%
3,156,981
– –
OLMA icon
2
Olema Pharmaceuticals
OLMA
$1.07B
$103M 7.44%
3,743,875
– –
DCPH
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$62.9M 4.53%
1,850,000
+750,000
+68% +$23.9M
BCYC
4
Bicycle Therapeutics
BCYC
$275M
$61.3M 4.42%
1,475,000
+760,000
+106% +$26.6M
DYN icon
5
Dyne Therapeutics
DYN
$4.2B
$58.8M 4.24%
3,619,392
+1,565,000
+76% +$27.7M
KRTX
6
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$56.3M 4.06%
460,000
+135,000
+42% +$15.6M
FMTX
7
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$49M 3.54%
2,115,000
+900,000
+74% +$21.3M
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$47.8M 3.45%
1,450,000
+1,100,000
+314% +$61.8M
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.5B
$45.2M 3.26%
+1,775,000
New +$41.4M
CMPS
10
Compass Pathways
CMPS
$1.54B
$41.8M 3.02%
1,400,000
+550,000
+65% +$18.5M
PMVP icon
11
PMV Pharmaceuticals
PMVP
$64M
$41.7M 3.01%
1,400,000
+1,193,436
+578% +$38.1M
DSGN icon
12
Design Therapeutics
DSGN
$748M
$40.7M 2.94%
2,772,501
+40,000
+1% +$665K
DICE
13
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$38M 2.74%
+1,160,251
New +$39.5M
CYTK icon
14
Cytokinetics
CYTK
$10.9B
$35.7M 2.58%
1,000,000
-400,000
-29% -$11.8M
NKTX icon
15
Nkarta
NKTX
$168M
$35.5M 2.56%
1,275,777
+273,395
+27% +$8.66M
KZR
16
DELISTED
Kezar Life Sciences
KZR
$35.4M 2.55%
410,000
+180,000
+78% +$11.9M
ALGS icon
17
Aligos Therapeutics
ALGS
$26M
$30.4M 2.2%
78,511
+70,000
+822% +$27.7M
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
$30.4M 2.19%
+510,000
New +$30.1M
VRDN icon
19
Viridian Therapeutics
VRDN
$2.18B
$24.7M 1.78%
+1,500,000
New +$22M
TIL icon
20
Instil Bio
TIL
$48.5M
$22.8M 1.65%
63,855
-20,988
-25% -$7.83M
VERV
21
DELISTED
Verve Therapeutics
VERV
$20.8M 1.5%
443,265
-315,000
-42% -$18.5M
LABP
22
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$20.5M 1.48%
140,500
+50,589
+56% +$6.57M
LENZ
23
LENZ Therapeutics
LENZ
$175M
$19.8M 1.43%
172,330
+19,364
+13% +$2.87M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$17.9M 1.29%
1,069,545
+130,000
+14% +$2.69M
TYRA icon
25
Tyra Biosciences
TYRA
$1.87B
$17.6M 1.27%
+1,003,394
New +$19.2M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2021 Portfolio in Review

As of Q3 2021, Logos Global Management held 74 positions worth $1.39B, up 17% from $1.19B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Logos Global Management deployed $227M of net new capital in Q3 2021, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was IDEAYA Biosciences: 1,775,000 shares worth $45.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kinnate Biopharma Inc. Common Stock, an estimated $26.9M trimmed.

  • Logos Global Management's largest Q3 2021 buy was IDEAYA Biosciences: 1,775,000 shares worth $45.2M.
  • Logos Global Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $61.8M increase.
  • Logos Global Management's biggest Q3 2021 reduction was Kinnate Biopharma Inc. Common Stock, cutting an estimated $26.9M.
  • Logos Global Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $31.2M.
  • Logos Global Management's ten largest holdings make up 55% of its $1.39B portfolio in Q3 2021.
  • Logos Global Management opened 16 new positions and closed 17 in Q3 2021.
  • Logos Global Management's portfolio value rose 17% quarter-over-quarter to $1.39B.

Based on Logos Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.